The clinical use of PET with 11C-acetate

American Journal of Nuclear Medicine and Molecular Imaging

Ilaria Grassi¹  Vincenzo Allegri¹  Stefano Fanti¹  Gian Carlo Montini¹  Paolo Castellucci¹  Joshua James Morigi¹  Cristina Nanni¹ 

关键词: Positron emission tomography (PET);    11C-acetate;    cancer;    cardiology;    prostate cancer;    liver cancer;    brain tumor;   

DOI  :  

学科分类：过敏症与临床免疫学

来源: e-Century Publishing Corporation

【 摘 要 】

The aim of this review is to evaluate clinical applications of ¹¹C-acetate positron emission tomography (PET). Acetate is quickly metabolized into acetyl-CoA in human cells. In this form it can either enter into the tricarboxylic acid cycle, thus producing energy, as happens in the myocardium, or participate in cell membrane lipid synthesis, as happens in tumor cells. ¹¹C-acetate PET was originally employed in cardiology, to study myocardial oxygen metabolism. More recently it has also been used to evaluate myocardial perfusion, as well as in oncology. The first studies of ¹¹C-acetate focused on its use in prostate cancer. Subsequently, ¹¹C-acetate was studied in other urological malignancies, as well as renal cell carcinoma and bladder cancer. Well differentiated hepatocellular carcinoma represents an ¹⁸F-fluoro-deoxyglucose (¹⁸F-FDG) PET pitfall, so many authors have proposed to use ¹¹C-acetate in addition to ¹⁸F-FDG in studying this tumor. ¹¹C-acetate PET has also been used in other malignancies, such as brain tumors and lung carcinoma. Some authors reported a few cases in which ¹¹C-acetate PET incidentally found multiple myeloma or rare tumors, such as thymoma, multicentric angiomyolipoma of the kidney and cerebellopontine angle schwannoma. Lastly, ¹¹C-acetate PET was also employed in a differential diagnosis case between glioma and encephalitis. The numerous studies on ¹¹C-acetate have demonstrated that it can be used in cardiology and oncology with no contraindications apart from pregnancy and the necessity of a rapid scan. Despite its limited availability, this tracer can surely be considered to be a promising one, because of its versatility and capacity to even detect non ¹⁸F-FDG-avid neoplasm, such as differentiated lung cancer or hepatocellular carcinoma.

【 授权许可】

Unknown